Pfizer Inc. $PFE Shares Acquired by Neuberger Berman Group LLC

Neuberger Berman Group LLC increased its position in shares of Pfizer Inc. (NYSE:PFE) by 203.8% during the 3rd quarter, Holdings Channel reports. The institutional investor owned 9,012,811 shares of the biopharmaceutical company’s stock after purchasing an additional 6,045,763 shares during the quarter. Neuberger Berman Group LLC’s holdings in Pfizer were worth $229,346,000 at the end of the most recent quarter.

Other large investors have also recently added to or reduced their stakes in the company. Brighton Jones LLC raised its holdings in Pfizer by 1,282.4% in the 4th quarter. Brighton Jones LLC now owns 666,318 shares of the biopharmaceutical company’s stock valued at $17,677,000 after buying an additional 618,117 shares during the period. Revolve Wealth Partners LLC boosted its stake in Pfizer by 12.5% during the fourth quarter. Revolve Wealth Partners LLC now owns 18,766 shares of the biopharmaceutical company’s stock worth $498,000 after buying an additional 2,087 shares during the period. United Bank boosted its stake in Pfizer by 12.4% during the second quarter. United Bank now owns 58,087 shares of the biopharmaceutical company’s stock worth $1,408,000 after buying an additional 6,415 shares during the period. Atlantic Union Bankshares Corp increased its position in shares of Pfizer by 36.5% during the second quarter. Atlantic Union Bankshares Corp now owns 101,345 shares of the biopharmaceutical company’s stock valued at $2,456,000 after acquiring an additional 27,097 shares during the last quarter. Finally, Ethos Financial Group LLC increased its position in shares of Pfizer by 214.5% during the second quarter. Ethos Financial Group LLC now owns 35,819 shares of the biopharmaceutical company’s stock valued at $868,000 after acquiring an additional 24,429 shares during the last quarter. 68.36% of the stock is currently owned by institutional investors and hedge funds.

Pfizer Trading Up 1.7%

NYSE PFE opened at $27.07 on Friday. The firm’s fifty day moving average price is $26.30 and its 200 day moving average price is $25.47. Pfizer Inc. has a 12 month low of $20.92 and a 12 month high of $27.94. The company has a debt-to-equity ratio of 0.71, a current ratio of 1.16 and a quick ratio of 0.87. The company has a market capitalization of $153.93 billion, a price-to-earnings ratio of 19.90 and a beta of 0.47.

Pfizer (NYSE:PFE) last announced its quarterly earnings results on Tuesday, February 3rd. The biopharmaceutical company reported $0.66 earnings per share for the quarter, beating analysts’ consensus estimates of $0.57 by $0.09. The firm had revenue of $17.56 billion during the quarter, compared to analysts’ expectations of $16.93 billion. Pfizer had a net margin of 12.42% and a return on equity of 20.48%. Pfizer’s quarterly revenue was down 1.2% compared to the same quarter last year. During the same period in the previous year, the company earned $0.63 earnings per share. On average, sell-side analysts expect that Pfizer Inc. will post 2.95 earnings per share for the current fiscal year.

Pfizer Dividend Announcement

The company also recently announced a quarterly dividend, which was paid on Friday, March 6th. Investors of record on Friday, January 23rd were given a $0.43 dividend. The ex-dividend date of this dividend was Friday, January 23rd. This represents a $1.72 dividend on an annualized basis and a dividend yield of 6.4%. Pfizer’s dividend payout ratio is 126.47%.

Pfizer News Summary

Here are the key news stories impacting Pfizer this week:

• Positive Sentiment: China approved Pfizer’s GLP‑1 weight‑management drug (Xianweiying / ecnoglutide), opening a large new market for its obesity franchise and reinforcing Pfizer’s push into metabolic drugs — this expands addressable market and supports long‑term revenue potential. China approves Pfizer GLP-1 drug for weight management
• Positive Sentiment: Analyst upgrade: Argus Research upgraded PFE to Buy and set a $35 target, citing progress in the GLP‑1 program and oncology pipeline — this can attract buy interest and boost sentiment among dividend and income investors. Argus Turns Bullish on Pfizer
• Positive Sentiment: Oncology wins: positive Phase 3 EV‑304 PADCEV results and FDA full approval for BRAFTOVI combinations were highlighted as re‑framing Pfizer’s long‑term growth prospects in oncology — supports diversification away from COVID revenues. Pfizer Obesity Nod In China And Cancer Wins
• Positive Sentiment: Pipeline expansion in China: Pfizer launched a Phase 1 heart‑failure candidate study in China, signaling continued local R&D investment that could yield future launches in a large market. Pfizer Adds New Early-Stage Heart Failure Candidate
• Neutral Sentiment: Investor attention & valuation debate: multiple articles note heightened retail/institutional interest and divergent valuation views (trending stock coverage, DCF vs. long‑term return debates) — increases volatility/volume but not a direct fundamental change. Pfizer Is a Trending Stock
• Neutral Sentiment: Competition & generics risk for GLP‑1s: coverage notes Pfizer will face crowded competition (and price pressure risk) even as it gains approvals — a mixed commercial outlook. Weight-Loss Drug Approved in China — Up Against Generic Rivals
• Negative Sentiment: Structural headwinds remain: analysts reiterate risks from declining COVID revenues, upcoming patent expirations and U.S. drug‑pricing pressures (IRA) that could limit near‑term growth despite new launches. Can Pfizer Reignite Growth?
• Negative Sentiment: Policy/legal noise: a recent court ruling awarded Pfizer $29M in an SEC settlement dispute (one‑time benefit), but legal and policy developments remain sources of uncertainty for investors. Judge approves Pfizer, SEC settlement

Analysts Set New Price Targets

Several equities analysts have recently commented on the stock. Guggenheim restated a “buy” rating on shares of Pfizer in a report on Wednesday, December 17th. TD Cowen reissued a “hold” rating on shares of Pfizer in a research report on Tuesday, December 30th. UBS Group assumed coverage on Pfizer in a research note on Tuesday, January 6th. They set a “neutral” rating and a $25.00 price target on the stock. Wolfe Research set a $24.00 price target on Pfizer and gave the stock an “underperform” rating in a research report on Wednesday, December 17th. Finally, Royal Bank Of Canada assumed coverage on Pfizer in a research note on Tuesday, February 24th. They issued an “underperform” rating and a $25.00 price objective for the company. One research analyst has rated the stock with a Strong Buy rating, five have assigned a Buy rating, fourteen have given a Hold rating and three have issued a Sell rating to the company’s stock. According to data from MarketBeat, Pfizer has a consensus rating of “Hold” and a consensus target price of $28.05.

Pfizer Profile

Pfizer Inc (NYSE: PFE) is a multinational biopharmaceutical company headquartered in New York City. Founded in 1849 by Charles Pfizer and Charles Erhart, the company researches, develops, manufactures and commercializes a broad range of medicines and vaccines for human health. Its activities span discovery research, clinical development, regulatory affairs, manufacturing and global commercial distribution across multiple therapeutic areas.

Pfizer’s portfolio and pipeline cover oncology, immunology, cardiology, endocrinology, rare diseases, hospital acute care and anti-infectives, along with a substantial vaccine business.